The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease

Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 142; no. 1; p. 40
Main Authors:	Steffel, Jan, Eikelboom, John W, Anand, Sonia S, Shestakovska, Olga, Yusuf, Salim, Fox, Keith A A
Format:	Journal Article
Language:	English
Published:	07.07.2020
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!